Loading organizations...

§ Private Profile · Durham, NC, USA
A biopharmaceutical company that developed drug candidates for central nervous system (CNS) disorders, focused on acute migraine.
Founded in 2005 by James White and Art Pappas, CoLucid Pharmaceuticals was a Durham, North Carolina-based biopharmaceutical company that developed innovative drug candidates for central nervous system disorders. The company's primary clinical asset was lasmiditan, a novel first-in-class oral and intravenous therapy originally discovered by Eli Lilly to provide safe and effective relief for acute migraine patients. Its broader preclinical pipeline also featured a conjugated stigmine platform with multiple candidates targeting wake promotion, chronic pain, Alzheimer’s disease, and various other psychiatric conditions. Backed by prominent venture capital investors including Pappas Ventures, Domain Associates, and Care Capital, the enterprise successfully completed a $55 million initial public offering in the year 2015. The business was subsequently acquired by pharmaceutical giant Eli Lilly in January 2017 for approximately $960 million, representing a final valuation of $46.50 per company share.
CoLucid Pharmaceuticals has raised $94.5M across 5 funding rounds.
CoLucid Pharmaceuticals has raised $94.5M in total across 5 funding rounds.
CoLucid Pharmaceuticals has raised $94.5M across 5 funding rounds. Most recently, it raised $37.0M Series C in January 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2015 | $37M Series C | DR. LUC Marengere | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures, Auriga Partners, Care Capital, Martin Edwards, Pappas Ventures, Pearl Street Venture Funds, Triathlon Medical Ventures | Announced |
| Aug 30, 2011 | $7.5M Venture Round | — | Care Capital, Domain Associates, ART Pappas, Pearl Street Venture Funds, Triathlon Medical Ventures | Announced |
| Aug 1, 2011 | $8M Series U | — | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures | Announced |
| Jun 1, 2008 | $25M Series B | — | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures | Announced |
| Jan 1, 2006 | $17M Series A | — | Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures | Announced |
CoLucid Pharmaceuticals has raised $94.5M in total across 5 funding rounds.
CoLucid Pharmaceuticals's investors include Dr. Luc Marengere, Cincy Tech, Domain Associates, Kleiner Perkins, Versant Ventures, Auriga Partners, Care Capital, Martin Edwards, Pappas Ventures, Pearl Street Venture Funds, Triathlon Medical Ventures, Art Pappas.
CoLucid Pharmaceuticals is a clinical-stage biopharmaceutical company (not a general “technology company”) focused on developing oral small‑molecule treatments for neurological conditions—most notably lasmiditan for acute migraine—which completed an IPO and was later acquired by a major pharma company after demonstrating clinical traction[1][4].[1]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Pharma Landscape
Quick Take & Future Outlook
If you’d like, I can: